Tetrasubstituted GHRH(1-29) analogue with enhanced enzymatic stability. Studied for pulsatile GH release via somatotroph GHRH receptor binding. Frequently paired with GHSR agonists for synergistic research protocols.
CJC-1295 without DAC (Drug Affinity Complex), also called "Modified GRF 1-29" or "Mod GRF 1-29", is a tetrasubstituted analogue of the first 29 amino acids of human GHRH. The four amino-acid substitutions (D-Ala² · Gln⁸ · Ala¹⁵ · Leu²⁷) confer resistance to proteolytic degradation while preserving full agonist activity at the GHRH receptor.
The D-Ala² substitution blocks DPP-IV cleavage. Gln⁸ resistance to asparagine deamidation, Ala¹⁵ resistance to trypsin-like proteases, and Leu²⁷ resistance to methionine oxidation. The combined modifications extend half-life from ~10 min (native GHRH) to ~30 min.
GHRHR Gs-coupling drives adenylyl cyclase activation. Intracellular cAMP rises, activating PKA which phosphorylates CREB and triggers GH gene transcription alongside immediate degranulation of pre-formed GH.
Unlike DAC-modified CJC-1295, the No-DAC version is rapidly cleared, allowing somatostatin negative-feedback to terminate the GH pulse. This preserves natural pulse architecture and avoids receptor desensitisation.
In rodent and canine research, 100–300 mcg CJC-1295 No-DAC produces GH peaks within 30–45 minutes that return to baseline within 2–3 hours. Repeated daily administration over weeks maintained pulse amplitude without measurable somatotroph desensitisation in published protocols.
Refs: Ionescu M, Frohman LA, JCEM (2006); Sackmann-Sala L et al., Mol Cell Endocrinol (2011)
Studies pairing CJC-1295 No-DAC with Ipamorelin or GHRP-6 demonstrate GH pulse amplitudes 3–5× higher than either compound alone. This synergistic profile underlies the widespread use of GHRH/GHRP combinations in GH-axis preclinical research.
Refs: Bowers CY et al., JCEM (2004)
Each batch is independently tested by a third-party ISO-accredited laboratory. The analysis below reflects Batch AV-2025-CJC-033, tested 28 February 2025.
| Test Parameter | Method | Specification | Result | Status |
|---|---|---|---|---|
| Identity | ESI-MS / MS-MS | Matches theoretical m/z | Confirmed (3367 Da) | PASS |
| Purity (HPLC) | RP-HPLC C18, 210nm | ≥98.0% | 99.3% | PASS |
| Water content | Karl Fischer | ≤8.0% | 5.7% | PASS |
| Heavy metals | ICP-MS | ≤10 ppm | <2 ppm | PASS |
| Endotoxins | LAL chromogenic | ≤10 EU/mg | <1 EU/mg | PASS |
| Form | Temperature | Duration |
|---|---|---|
| Lyophilised powder | −20°C (preferred) or 2–8°C | 24 months / 12 months |
| Reconstituted (BAC water) | 2–8°C | ≤28 days |
| Reconstituted (saline) | 2–8°C | ≤7 days |
Wipe vial with 70% IPA.
For 2 mg vial, add 2 mL BAC water → 1 mg/mL stock. Inject slowly along the inner wall.
Swirl gently. CJC-1295 No-DAC is highly water-soluble; clear dissolution within 60 seconds.
Store at 2–8°C. Avoid freeze-thaw of reconstituted solution.
CJC-1295 With DAC produces tonic, sustained GH elevation (half-life ~8 days) which can desensitise somatotrophs and disrupt natural pulse architecture. The No DAC version produces clean pulses that decline naturally, allowing somatostatin feedback to maintain pulse integrity. Most modern research protocols favour No DAC for these physiological reasons.
The two compounds activate independent pituitary receptor systems: CJC-1295 stimulates GHRHR (Gs/cAMP pathway), Ipamorelin stimulates GHSR-1a (Gq/PLC pathway). Combined activation produces synergistic GH pulse amplitudes 3–5× greater than either compound alone — the foundational rationale for GHRH+GHRP pairings in research.
Most preclinical protocols administer pre-sleep (aligned with natural nocturnal GH pulse peak) or post-exercise (when growth hormone pulses are physiologically primed). Pre-meal fasted administration is preferred — elevated glucose and free fatty acids blunt the GH response via increased somatostatin tone.
Published preclinical data over multi-week daily administration did not show somatotroph desensitisation or pulse-amplitude attenuation. This contrasts with CJC-1295 With DAC, where sustained tonic GHRH receptor activation can produce receptor down-regulation. The No DAC version's clean pulse pattern is hypothesised to preserve receptor responsiveness.
Independently verified by third-party ISO-accredited laboratory. COA available on request.
View CJC-1295 in Store → Reconstitution Protocol Guide